Menu
Not yet recruiting NCT05320367

A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users

Phase I / Phase II Interventional Cannabis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cannabis, placebo.
Who it may be relevant to
Registry conditions: Cannabis. Basic parameters: 21 years — 49 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized, Triple Blinded Cross-over Placebo Controlled Study of Effects of Inhaled Cannabidiol in Healthy Occasional Cannabis Users

Overview

The purposes of this study are 1) to determine if the administration of different low doses of CBD (5 mg, 20 mg, 50 mg and 100 mg) result in detectable subjective pleasant drug effect compared to placebo and 2) to qualitatively explore whether low dose CBD is associated with effects that are not detected with the available research tools.

Detailed description

Cannabis contains over 100 cannabinoids, the two most prominent being Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). A growing body of evidence exists surrounding the effects of both THC and CBD, however, less is known about the specific effects of CBD concentrations alone. Most existing data regarding the effects of CBD come from studies where this compound is administered in high doses in a therapeutic context, and where the subject can be administered either CBD, THC or both together. These contexts are not representative of the current use by many consumers. Indeed, several available products contain CBD at much lower doses. The overall objective of this study is to evaluate the acute behavioral and biological effects of low doses of CBD (between 5-100mg) and placebo in occasional cannabis users. Potential outcomes not detected with usual assessment tools designed to evaluate THC-induced effects will also be explored.

Interventions

  • Drug Cannabis, placebo
    Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.

Primary outcome measures

  • Pleasant drug effect [Time frame: T1(10 minutes after inhalation)]
  • Pleasant drug effect [Time frame: T2 (80 minutes after inhalation)]
  • Pleasant drug effect [Time frame: T3 (140 minutes after inhalation)]
Secondary outcome measures (10)
  • Drug Effects associated with cannabis administration [Time frame: T1 (10 minutes after inhalation)]
  • Drug Effects associated with cannabis administration [Time frame: T2 (80 minutes after inhalation)]
  • Drug Effects associated with cannabis administration [Time frame: T3 (140 minutes after inhalation)]
  • Change in dissociation [Time frame: Baseline and after inhalation at (10 minutes, 80 minutes)]
  • Cannabis-Specific Subjective Effects [Time frame: T3 (140 minutes after inhalation)]
  • Change in Affect [Time frame: Baseline and after inhalation at (10 minutes, 80 minutes, 140 minutes)]
  • Change in Anxiety Symptoms [Time frame: Baseline and after inhalation at (10 minutes, 80 minutes and 140 minutes)]
  • Change in Safety [Time frame: Baseline and after inhalation at (10 minutes, 80 minutes, 140 minutes)]
  • Change on cognition [Time frame: Baseline and after inhalation at T2 (80 minutes).]
  • Visit Intoxication Assessment [Time frame: End of the visit, approximatively 180 minutes after inhalation]

Eligibility criteria

Inclusion criteria

  • Between 21 and 49 years of age, inclusively;
  • Have used cannabis at least once in lifetime AND have used cannabis three days or less in the 28 days prior to enrollment;
  • Be able to provide a signed informed consent;
  • Willing to comply with study procedures and requirements as per protocol, including to abstain from using other cannabis products or any drugs (except alcohol or nicotine) 7 days prior to study visits;
  • Have a forced expiratory volume in first second (FEV) sup 90 %;
  • Able to communicate and understand English or French language;
  • For female participants:

a. Without childbearing potential, defined as: i. postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or ii. Documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or

b. With childbearing potential: i. Must have negative pregnancy test result at screening and at subsequent visits.

ii. AND have no pregnancy plan while on the trial iii. AND must agree to use a medically accepted method of birth control throughout the study.

Exclusion criteria

  • Any disabling medical conditions, as assessed by medical history, physical exam, vital signs and/or laboratory assessments that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent;
  • Severe psychiatric condition (e.g. history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or current suicidality, acute depression or anxiety disorder based on the Mini International Neuropsychiatric Interview);
  • Any other disabling, unstable, or acute mental condition that, in the opinion of the study physician, precludes safe participation in the study or ability to provide informed consent;
  • Known chronic liver disease or aspartate transaminase/alanine transaminase (AST/ALT) two times higher than upper limit of normal values at screening visit;
  • Blood pressure higher than 130/80 mmHg;
  • Kidney disorders;
  • Bleeding disorders;
  • Current moderate or severe DSM-5 (The Diagnostic and Statistical Manual of Mental Disorders) substance use disorder (except nicotine) according to the Structured Clinical Interview for DSM-V ;
  • Currently pregnant,breastfeeding or planning to become pregnant either at screening or while enrolled in the study;
  • Pending legal action or other reason that, in the opinion of the study physician, might prevent study completion;
  • Use of medication within 7 days of experimental sessions, which, in the opinion of the investigator, may interact with cannabis;
  • Participation in clinical studies or undergoing other investigational procedures involving cannabis or cannabinoids administration within 30 days prior to randomization;
  • Resting heart rate over 100 beats per minute;
  • Current body mass index (BMI) over 29.9 kg/m2;
  • Any clinically significant electrocardiogram abnormalities at screening visit.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05320367 · 21.361

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗